Unsaturated olefine aldehyde compound with anti-inflammatory and phlegm-eliminating activity as well as preparation method and application of unsaturated olefine aldehyde compound
The unsaturated enal compound TRX extracted from the intestinal endophytic fungus Talaromyces rugulosus GIZ45-A37 strain of the bat moth, solved the problem of high secretion of mucus and irrepressible inflammation in COPD patients, and achieved low toxicity and efficient anti-inflammatory expectoration. Effects, with the potential to develop anti-inflammatory expectorant drugs.
Patent Information
- Application Number
- CN202411120588.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-15
AI Technical Summary
Inflammation and respiratory obstruction caused by high mucus secretion in patients with chronic obstructive pulmonary disease (COPD), the development of existing anti-inflammatory expectorant drugs is difficult to effectively inhibit inflammation and mucus secretion, and there are safety and efficiency problems.
An unsaturated enal compound was extracted from the strain of the intestinal endophytic fungus Talaromyces rugulosus GIZ45-A37, and was purified by ethyl acetate extraction, silica gel column chromatography, reverse phase ODS column chromatography and high performance liquid chromatography. TRX, which has significant anti-inflammatory expectorant activity, was obtained.
The compound TRX exhibits low cytotoxicity, stability and significant anti-inflammatory expectorant activity, is easy to be produced in industrial form, and has broad application prospects, especially in the treatment of COPD.
Smart Images

Figure CN119019355A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of natural products, and specifically relates to an endophytic fungus strain in the intestinal tract of a bat moth and a compound with anti-inflammatory and expectorant activity produced by fermentation thereof. Background Art
[0002] Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammatory disease characterized by airflow limitation. It progressively deteriorates lung function, seriously affecting the patient's ability to work and quality of life. It is a heterogeneous, systemic disease that continues to worsen and is not completely reversible in modern society. It is the third leading cause of death in the world and has risen to the fifth place in the world's economic burden of disease. COPD is mainly related to the nonspecific chronic inflammatory response of the bronchial mucosa, blood vessels, alveoli, etc. caused by long-term exposure of patients to harmful gases such as chemical particles or cigarette smoke. One of the important pathological characteristics of COPD is mucus hypersecretion. Under normal circumstances, a moderate amount of mucus secretion has a protective effect on the airway, but under pathological conditions, there is often an abnormality in the amount or quality of mucus, and excessive mucus accumulation will aggravate local respiratory inflammation and infection. Mucin 5AC (Mucin 5AC, 5AC) is the main protein component of airway mucus, and the large amount of MUC5AC secretion is the main reason for the hypersecretion of mucus. COPD also has a high mortality rate in my country, especially in the acute exacerbation of COPD (AECOPD), when patients have severe inflammatory reactions in their respiratory tract, which further aggravates irreversible obstruction of the respiratory tract, fatigue of respiratory muscles, and often progresses to type II respiratory failure, further increasing the mortality rate and making clinical treatment more difficult. Inhibiting the occurrence and development of inflammation and mucin is an effective means to alleviate and treat chronic diseases such as COPD. Therefore, it is very necessary to develop safe and efficient anti-inflammatory and expectorant preparations.
[0003] Fungi are one of the important sources of compounds with novel structures and unique activities. The applicant previously isolated a new macrolide compound with significant anti-inflammatory activity from the metabolites of the endophytic fungus GIZ45-A37 in the intestines of bat moths. The applicant further studied the metabolites of the endophytic fungus GIZ45-A37 in the intestines of bat moths (deposit number: GDMCC No. 64050) and found a new unsaturated aldehyde compound with significant anti-inflammatory and expectorant activity. Summary of the invention
[0004] The object of the present invention is to provide a novel compound obtained by fermenting Talaromyces rugulosus GIZ45-A37 strain and having significant anti-inflammatory and expectorant activity, namely an unsaturated olefinic aldehyde compound.
[0005] The present invention provides an unsaturated olefinic aldehyde compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
[0006]
[0007] Wherein, R1, R2, R3, R4, and R5 are independently selected from methyl or hydroxyl.
[0008] Furthermore, the above R1 is a methyl group.
[0009] Furthermore, the above R2 is a methyl group.
[0010] Furthermore, the above R3 is a methyl group.
[0011] Furthermore, the above R4 is a hydroxyl group.
[0012] Furthermore, the above R5 is a methyl group.
[0013] Furthermore, the structure of the above compound is as follows:
[0014]
[0015] The present invention also provides a method for preparing the above compound, which is separated from the fermentation culture of Talaromyces rugulosus GIZ45-A37.
[0016] The specific steps include:
[0017] S1. inoculating Talaromyces rugulosus GIZ45-A37 into a fermentation medium, and culturing to obtain a fermentation product;
[0018] S2, adding ethyl acetate to the fermentation product obtained in S1, mixing, extracting, and filtering to obtain an extract;
[0019] S3, concentrating the extract obtained in S2 under reduced pressure to obtain a crude extract;
[0020] S4, subjecting the crude extract obtained in S3 to silica gel column chromatography, using an eluent consisting of petroleum ether and ethyl acetate, and performing gradient elution in a volume ratio of petroleum ether to ethyl acetate of 50:1, 25:1, 10:1, 5:1, 2:1, and 1:1 in sequence, collecting the eluent with a volume ratio of petroleum ether to ethyl acetate of 5:1, and drying to obtain a crude product;
[0021] S5, subjecting the crude product obtained in S4 to reverse phase ODS column chromatography, using an eluent consisting of methanol and water, and performing gradient elution in the order of methanol concentration of 20%, 40%, 60%, and 80%, collecting the eluent of 40% to 60% methanol / water, and drying to obtain a crude product;
[0022] S6, subjecting the crude product obtained in S5 to gel Sephadex LH-20 column chromatography, using dichloromethane-methanol v / v 2:1 as eluent, collecting the eluent for high performance liquid chromatography detection, using C18 chromatographic column, 60% methanol / water, 254 nm wavelength as chromatographic conditions for detection, collecting the eluent containing the main peak, and drying to obtain a crude product;
[0023] S7, purifying the crude product obtained in S6 by medium- and high-pressure preparative liquid phase purification.
[0024] Furthermore, the fermentation medium described in step S1 above is composed of the following components in parts by weight: 90-100 g of rice, 100 ml of water, and sterilized by high-pressure steam at 120° C. for 20 min.
[0025] Furthermore, the culturing in step S1 is performed by placing the culture medium at a constant temperature of 25° C. for 30 days;
[0026] Furthermore, in step S2, ethyl acetate is added to the fermentation product obtained in S1, the mass volume ratio of the fermentation product to ethyl acetate is 1:3, the extraction is ultrasonic extraction for 15 minutes, the number of extractions is 3 times, the power used for ultrasonic extraction is 400W, and the operating frequency is 40KHz.
[0027] Furthermore, in the high pressure preparative liquid chromatography purification in step S7, the mobile phase is a mixed solution of acetonitrile and water, wherein the volume percentage of acetonitrile is 70%.
[0028] The present invention also provides the use of the above-mentioned compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof in the preparation of an anti-inflammatory and expectorant drug; preferably, the drug is a drug for preventing and treating chronic obstructive pulmonary disease (COPD).
[0029] The present invention also provides a medicine, which is a preparation prepared by using the above-mentioned compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient, and adding pharmaceutically acceptable excipients or auxiliary ingredients.
[0030] Beneficial effects of the present invention:
[0031] (1) The bat moth intestinal endophytic bacteria strain of the present invention can be fermented to produce a new compound, which has stable performance, low cytotoxicity, and significant anti-inflammatory and expectorant activity.
[0032] (2) The compound of the present invention is produced by solid fermentation of fungi, and can be obtained by extracting the fermentation product with ethyl acetate, and then separating and purifying it by silica gel column chromatography, reversed-phase ODS column chromatography, gel column chromatography and high performance liquid chromatography. The separation steps are simple, the implementation is convenient, and it is easy to industrialize large-scale production, and has broad application prospects.
[0033] Deposit of biological materials:
[0034] Talaromyces rugulosus GIZ45-A37 was deposited in the Guangdong Microbiological Culture Collection Center (GDMCC) on November 22, 2023. The deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province, Postal Code: 510070, and the deposit number is GDMCC No.64050.
[0035] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0036] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The high-resolution mass spectrometry result spectrum of the compound having the structure of Formula I of the present invention is shown in FIG.
[0038] Figure 2 The compound of the present invention having the structure of formula I 1 H NMR spectrum.
[0039] Figure 3 The compound of the present invention having the structure of formula I 13 C NMR spectrum.
[0040] Figure 4 The compound of the present invention having the structure of formula I 1 H- 1 H COSY spectrum.
[0041] Figure 5 The HSQC spectrum of the compound having the structure of Formula I of the present invention.
[0042] Figure 6 It is the HMBC spectrum of the compound having the structure of formula I of the present invention.
[0043] Figure 7 The NOESY spectrum of the compound having the structure of formula I of the present invention.
[0044] Figure 8 It is the growth rate of cells at different concentrations of the compound having the structure of formula I of the present invention.
[0045] Fig. 9The results are the results of the assay of the compounds of the present invention having the structure of Formula I inhibiting the secretion of IL-6 from cells.
[0046] Fig.10 The results are the results of the assay of the compound with structure I of the present invention inhibiting the secretion of MUC5AC in cells. DETAILED DESCRIPTION
[0047] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.
[0048] Example 1. Preparation of the compounds of the present invention
[0049] 1. Fermentation of bacteria
[0050] 1. Inoculate the strain Talaromyces rugulosus GIZ45-A37 onto a PDA medium plate and culture at 28°C in the dark for 7 days to obtain plate seeds.
[0051] 2. Transfer the seeds obtained in step 1 to liquid seed culture medium, culture in the dark at 28°C and 150rpm for 4 days to obtain seed culture solution.
[0052] Seed culture medium: The solvent is potato juice (the preparation method of potato juice: 200g potato, add about 1L of water, boil for 30min, filter, and make up the filtrate to 1L), the solute and its content are as follows: glucose 20g / L, agar 20g, sterilize and set aside.
[0053] 3. Inoculate about 10 mL of seed culture solution into a flask containing fermentation medium and culture at a constant temperature of 25°C for 30 days.
[0054] 4. Preparation method of fermentation medium: Take 100g rice, add 100ml water, put into a 500mL Erlenmeyer flask, and sterilize under high pressure (120℃, 20min).
[0055] 2. Extraction, separation and purification of the compounds of the present invention
[0056] 1. Add 300 ml of ethyl acetate to the fermented flask, perform ultrasonic extraction at 30°C for 15 min, extract 3 times, the ultrasonic power is 400 W, the operating frequency is 40 KHz, filter the extract, combine all the extracts and concentrate under reduced pressure at 40°C to obtain the total extract.
[0057] 2. The total extract was dissolved in ethyl acetate and then mixed with column chromatography silica gel in a mass ratio of 1:1 and dried. The sample was dry-loaded and subjected to silica gel column chromatography (filler was 200-300 mesh silica gel powder). The mixture was eluted with a petroleum ether / ethyl acetate mixed solution (v / v: 50:1, 25:1, 10:1, 5:1, 2:1, 1:1, 0:100). The eluate with a volume ratio of petroleum ether to ethyl acetate of 5:1 was collected and rotary evaporated to obtain a crude product A.
[0058] 3. The crude product A was further eluted with a reverse column (filler: ODS C-18 column chromatography silica gel, gradient elution, eluent: methanol / water mixed solvent, eluted with volume fractions of 20%, 40%, 60%, 80% methanol / water in sequence, eluted with 2 column volumes of solvent respectively, collected the 40% to 60% methanol / water eluate, concentrated and dried under reduced pressure to obtain a crude product A-1.
[0059] 4. The crude product A-1 was further separated by gel Sephadex LH-20 column chromatography, eluted with dichloromethane-methanol (v / v 2:1) as the eluent, and the eluate was collected for high performance liquid chromatography detection, and the chromatographic conditions were C18 chromatographic column (4.6×100mm, 2.7μM), volume fraction 60% methanol / water, flow rate 0.5ml / min, and wavelength 254nm. The eluate containing the main peak (retention time 7.15min) was collected and dried to obtain the crude product A-2; prepared as a white powder by medium and high pressure preparative liquid chromatography (C18 chromatographic column: 10×250mm, 5μM; flow rate: 1ml / min, mobile phase: 70% acetonitrile / water, v / v; wavelength: 254nm; Rt=21.5min):
[0060] 5. Figure 1 The high-resolution mass spectrometry result spectrum of the compound having the structure of Formula I of the present invention is shown in FIG. Figure 2 The compound of the present invention having the structure of formula I 1 HNMR spectrum. Figure 3 The compound of the present invention having the structure of formula I 13 C NMR spectrum. Figure 4 The compound of the present invention having the structure of formula I 1 H- 1 H COSY spectrum. Figure 5 The HSQC spectrum of the compound having the structure of Formula I of the present invention. Figure 6 It is the HMBC spectrum of the compound having the structure of formula I of the present invention. Figure 7 The NOESY spectrum of the compound having the structure of formula I of the present invention.
[0061] The compound of the present invention is a white solid powder, easily soluble in chloroform, methanol and DMSO, HR-ESI-MS: m / z 235.13399 [MH] - (like Figure 1 ), 1 H NMR (600MHz, CDCl3) spectrum H :9.62 (1H, d, J = 7.8 Hz), possibly the signal of aldehyde hydrogen, δ H :7.41 (1H, dd, J1 = 15.0 Hz, J2 = 15.0 Hz), 6.20 (1H, dd, J1 = 15.0 Hz, J2 = 7.8 Hz), 6.40 (1H, d, J = 11.4 Hz), according to the displacement and coupling constants, it can be inferred that the three hydrogen atoms are trans double bond hydrogen atoms and are in adjacent positions. 5.73 (1H, s) may also be a double bond hydrogen atom. The other hydrogen atom signals are distributed in δ H :4.60(1H,s),3.50(2H,m),1.87(3H,d,J=1.2Hz),1.51(3H,s),1.24(3H,m),1.17(3H,s). 13 The C NMR (150MHz, CDCl3) spectrum shows 14 carbon atom signals, among which δ C : The six carbon atom signals of 147.8, 146.9, 135.2, 132.4, 131.3 and 128.0 are double bond carbon atom signals, δ C :194.0 is the signal of aldehyde carbon atom. DEPT spectrum can infer that the compound has 3 quaternary carbons (C), 7 tertiary carbons (CH), and 4 primary carbons (CH3). 1 H- 1 H COSY spectrum shows δ H :9.62 and 6.20, δ H :7.41 vs 6.20,6.40,δ H :3.50 and 1.24 respectively, indicating that the hydrogen atoms are in adjacent positions. H :6.40 and δ C :128.0,δ H :5.73 and δ C :131.3,δ H :4.60 and δ C :84.7,δ H :3.50 and δ C :77.2,δ H :1.87 and δ C :14.1,δ H :1.51 and δ C :18.4,δ H:1.24 and δ C :12.9,δ H :1.19 and δ C :23.6 show correlated signals, which can be assigned to carbon atoms and corresponding hydrogen atoms. The HMBC spectrum shows that hydrogen atoms are remotely coupled to carbon atoms, such as δ H :9.62 and δ C :132.4 has long-range coupling related signals. Combining the above spectrum information, the structure of the compound was identified.
[0062] 6. NMR characterization data are as follows:
[0063] 1 H NMR (600MHz,CDCl3)δ H :1.17(3H,s),1.23(3H,d,J=6.0Hz),1.51(3H,s),1.87(3H,d,J=1.2Hz),3.50(1H,q,J=6.0Hz),4.46(1H,s),5.73(1H,s), 6.19(1H,dd,J1=7.8Hz,J2=15.0Hz), 6.39(1H,d,J=11.4Hz), 7.41(1H,dd,J1=11.4Hz, J2=15.0Hz), 9.62(1H,d,J=7.8Hz), see Figure 2 .
[0064] 13 C NMR (150MHz,CDCl3)δ C :12.7(q),14.1(q),18.4(q),23.6(q),67.1(s),77.3(d),84.7(d),128 .0(d),131.3(d),132.4(d),135.2(s),146.9(d),147.8(s),194.0(d), see Figure 3 .
[0065] The structure of the compound was identified and its molecular formula was C 14 H 20 O3, the structure is as follows:
[0066]
[0067] The compound was named TRX.
[0068] The following experimental examples demonstrate the beneficial effects of the compounds of the present invention.
[0069] Example 2: Identification of the endophytic fungus strain Talaromyces rugulosus of the present invention
[0070] The Talaromyces rugulosus GIZ45-A37 of the present invention is isolated from the intestine of bat moth, identified by Guangdong Institute of Microbiology, and stored in a refrigerator at 4°C using a PDA slant culture medium.
[0071] Based on the DNA sequence of the internal transcribed spacer (ITS), the fungal strain was identified as Talaromyces rugulosus by NCBI BLAST analysis. The following sequences were used in the BLAST search.
[0072] SEQ ID NO.1:
[0073] CGTTGTGACTGCGGAGGTCATTACCGAGTGCGGGTTCCAACGAGCCCAACCTCCCACCCGTGTTTACCATGACCGCGTTGCCTCGGCGGGCCCACTGGGGCCTGGCCCCGGTCGCCGGGGGGCTTCTGCCCCCGGGTCCGCGCCCGCC GAAGCGCCCTGGAACCCTGTCTGAATAGTGAGTCTGAGTCTATGATTAAATCATTAAAACTTTCAACAACGGATCTCTTGGTTCCGGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCCGTGAATCAT CGAATCTTTGAACGCACATTGCGCCCCCTGGCATTCCGGGGGGCATGCCTGTCCGAGCGTCATTTCTGCCCTCCAGCCCGGCTGGGTGTTGGGTGTTGTCCCCCCGGGGACACGCCTCAAAGGCAGTGGCGGCGCCGCGTCGGGTCCTC GAGCGTATGGGGCTTTGTCACCCGCTCGGGACGGACTCGTCGGCGCTGGTCTTCCTCCAGGCGACCCTTCGGGGCCCGTCTACCTTCGGTTGACCTCGGATCAGGTAGGGTTACCCGCTGAACTTAAGCATATCAATAAGCGGAGAGAA
[0074] Named: Talaromyces rugulosus GIZ45-A37, it was deposited in Guangdong Microbiological Culture Collection Center (GDMCC) on November 22, 2023, with the deposit address: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province, zip code 510070, and the deposit number is GDMCC No. 64050. The strain is disclosed in CN202311729129.1, and the invention name is: A macrolide compound with anti-inflammatory activity and its preparation method and application in the Chinese patent application.
[0075] Example 3: Anti-inflammatory activity test of the compounds of the present invention
[0076] Interleukin-6 (IL-6) is an important inflammatory factor, and increased IL-6 expression promotes the development of inflammation. Therefore, IL-6 can be used as an indicator substance for the development of inflammation, and may also be a potential target for the treatment of COPD (Winslow S, Odqvist L, Diver S, et al. Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD [J]. Eur Respir J. 2021, 58 (4): 1-14.). The present invention acts on human bronchial epithelial cells Beas2b induced by lipopolysaccharide (LPS) by the compound prepared by Example 1 (hereinafter referred to as TRX), and the anti-inflammatory activity of TRX is evaluated by detecting the IL-6 content produced in the cell culture supernatant.
[0077] 1. Reagents and Instruments
[0078] Human bronchial epithelial cells Beas-2b; lipopolysaccharide (LPS); DMEM high glucose medium; fetal bovine serum (FBS); phosphate buffered saline (PBS); dimethyl sulfoxide (DMSO); 1% P / S double antibody; enzyme-linked immunosorbent assay kit (ELISA kit); precision electronic balance; biological safety cabinet; carbon dioxide incubator; inverted microscope; low-speed refrigerated centrifuge; microplate reader; digital display constant temperature water bath.
[0079] 2. Culture of Beas-2b cells
[0080] The basic culture medium is DMEM culture medium + 10% FBS + 1% P / S double antibody; the culture conditions are 37°C, 5% CO2 and saturated humidity; after culturing for 2 to 3 days, the cell density reaches 90% and can be used for experiments.
[0081] 3. Cell Viability Assay
[0082] Beas-2b cells in the logarithmic growth phase were taken and prepared into 2×10 5 The single cell suspension of 100 μl / well was inoculated into a 96-well plate (3 replicates per group). After the cells adhered to the wall, they were cultured until the confluence was about 80%. The original culture medium was discarded, and the control group added normal culture medium (1 μl of compound solvent, 99 μl of DEME culture medium), and the TRX group added culture medium containing different concentrations of compounds (1 μl of TRX compound solution, 99 μl of DEME culture medium, and the final concentration of TRX was 100 μM, 50 μM, 25 μM, 12.5 μM, and 6.25 μM). The culture was continued for 24 hours, and the cell growth state and culture medium changes were observed under an inverted microscope. After the culture was completed, 10 μl of cck-8 working solution was added to each well, incubated at 37°C for 2 hours, and detected at 450 nm.
[0083] Cell inhibition rate = 1-(drug-added well-background value) / (control well-background value) × 100%
[0084] The experimental results are as follows Figure 8 As shown: TRX has no significant inhibitory effect on Beas2b cells within the concentration range of 6.25μM to 100μM, indicating that TRX is safe within this range and has very low cytotoxicity.
[0085] 4. Determination of anti-inflammatory activity of compound TRX
[0086] Beas-2b cells in the logarithmic growth phase were taken and the cell density was adjusted to 2×10 6 / ml, and 500μl / well of cells were inoculated into a 48-well plate. After the cells adhered, they were cultured until the degree of confluence was about 80%. The culture medium was discarded, and a control group, a model group, and a TRX group were set up. The control group did not add LPS and TRX, the model group added LPS solution (LPS final concentration was 1μg / ml) to the culture medium, and the TRX group added fresh DMEM culture medium containing LPS (LPS final concentration was 1μg / ml) and TRX solution (TRX final concentration was 10μM and 20μM), and the culture was continued for 24h. After the culture was completed, the supernatant of each well was collected into a 1.5ml centrifuge tube, centrifuged at 6000 rpm for 5min, and the supernatant was transferred to another 1.5ml centrifuge tube and stored at -20℃ for ELISA detection. The IL-6 content was detected according to the instructions of the ELISA kit.
[0087] The experimental data were expressed as mean ± standard deviation (x ± s), and the inter-group comparison was performed using SPSS 22.0 statistical software for one-way analysis of variance for significant differences. # p<0.05, ##p<0.01 indicates a significant difference, which is statistically significant; Comparison between the sample group and the model group * p<0.05, ** p<0.01 indicates a significant difference and is statistically significant.
[0088] like Fig. 9 As shown, the IL-6 content in the model group was significantly different from that in the control group, indicating that the model was successfully established. The IL-6 content in the TRX group was significantly lower than that in the model group, indicating that TRX has the ability to inhibit the expression of IL-6, thereby exerting an anti-inflammatory effect.
[0089] Example 4: Expectorant activity test of the compounds of the present invention
[0090] One of the important pathological characteristics of chronic inflammatory diseases of the airways is mucus hypersecretion. Under normal circumstances, an appropriate amount of mucus secretion has a protective effect on the airways, but under pathological conditions, there are often abnormalities in the amount or quality of mucus, and excessive mucus accumulation will aggravate local respiratory inflammation and infection. Mucin 5AC (5AC) is the main protein component of airway mucus, and the large amount of MUC5AC secretion is the main cause of mucus hypersecretion (Zhao et al. Effects of PM2.5 on mucus secretion and tissue remodeling in a rabbit model of chronic rhinosinusitis. Int Forum Allergy Rhinol, 2018, 8(11): 1349-13552).
[0091] 1. Reagents and Instruments
[0092] Human bronchial epithelial cells Beas-2b; exogenous epidermal growth factor (EGF); DMEM high glucose medium; fetal bovine serum (FBS); phosphate buffered saline (PBS); dimethyl sulfoxide (DMSO); 1% P / S double antibody; mucin 5AC (MUC5AC) enzyme-linked immunosorbent assay kit (ELISA kit); precision electronic balance; biological safety cabinet; carbon dioxide incubator; inverted microscope; low-speed refrigerated centrifuge; microplate reader; digital display constant temperature water bath.
[0093] 2. Culture of Beas-2b cells
[0094] The basic culture medium is DMEM culture medium + 10% FBS + 1% P / S double antibody; the culture conditions are 37°C, 5% CO2 and saturated humidity; after culturing for 2 to 3 days, the cell density reaches 90% and can be used for experiments.
[0095] 3. Determination of the expectorant activity of compounds
[0096] Human Beas-2b cells were cultured in DMEM medium containing 10% FBS. A control group, a model group, and a sample group were set up. The cells were inoculated into 48-well plates and placed in an incubator at 37°C and 5% CO2. When the cell confluence reached 70%, the serum-free medium was replaced in all three groups of cells. The model group was stimulated with exogenous epidermal growth factor (EGF) (25 ng / ml), and the TRX group was stimulated with fresh DMEM medium containing LPS and TRX solution (final concentrations of 10 μM and 20 μM). The cells were stimulated for 24 hours, and the culture supernatant was collected. The cell supernatant was centrifuged at 6000 rpm for 5 minutes, and the supernatant was transferred to another 1.5 ml centrifuge tube and stored at -20°C for ELISA detection. The MUC5AC content was detected according to the instructions of the ELISA kit.
[0097] The experimental data are expressed as mean ± standard deviation. Indicates that the inter-group comparison was performed using SPSS22.0 statistical software for one-way analysis of variance for significant differences. * indicates a significant difference p<0.05, ** indicates a significant difference p<0.01.
[0098] like Fig.10 As shown in the figure, the MUC5AC content in the model group was significantly different from that in the control group, indicating that the model was successfully established. The MUC5AC content in the TRX group was significantly lower than that in the model group, indicating that TRX has the ability to inhibit the expression activity of cellular MUC5AC, thereby exerting an expectorant effect.
[0099] Chronic obstructive pulmonary disease (COPD) is a chronic disease closely related to inflammation and mucus secretion. Inhibiting the development of inflammation and mucus is an important method and approach for treating COPD. The compound TRX of the present invention has significant anti-inflammatory and expectorant activity, and the active concentration is as low as 10 μM. Cell viability experiments show that the cytotoxicity is very small. Therefore, the compound TRX of the present invention has the potential to develop anti-inflammatory and expectorant drugs for treating COPD.
Claims
1. An unsaturated olefinic aldehyde compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof: in, R1, R2, R3, R4, and R5 are independently selected from methyl or hydroxyl.
2. The unsaturated olefinic aldehyde compound according to claim 1, characterized in that: R1 is methyl; or R2 is methyl; Or R3 is methyl; or R4 is hydroxyl; or R5 is methyl.
3. The unsaturated olefinic aldehyde compound according to claim 2, characterized in that: The structure of the compound is as follows:
4. A method for preparing the unsaturated olefinic aldehyde compound according to claim 3, characterized in that: The invention is separated from the fermentation culture of Talaromyces rugulosus GIZ45-A37. The deposit number of the Talaromyces rugulosus GIZ45-A37 is GDMCC No.64050.
5. The preparation method according to claim 4, characterized in that: The steps include: S1. inoculating Talaromyces rugulosus GIZ45-A37 into a fermentation medium, and culturing to obtain a fermentation product; S2, adding ethyl acetate to the fermentation product obtained in S1, mixing, extracting, and filtering to obtain an extract; S3, concentrating the extract obtained in S2 under reduced pressure to obtain a crude extract; S4, subjecting the crude extract obtained in S3 to silica gel column chromatography, using an eluent consisting of petroleum ether and ethyl acetate, and performing gradient elution in a volume ratio of petroleum ether to ethyl acetate of 50:1, 25:1, 10:1, 5:1, 2:1, and 1:1 in sequence, collecting the eluent with a volume ratio of petroleum ether to ethyl acetate of 5:1, and drying to obtain a crude product; S5, subjecting the crude product obtained in S4 to reverse phase ODS column chromatography, using an eluent consisting of methanol and water, and performing gradient elution in the order of methanol concentration of 20%, 40%, 60%, and 80%, collecting the eluent of 40% to 60% methanol / water, and drying to obtain a crude product; S6, subjecting the crude product obtained in S5 to gel Sephadex LH-20 column chromatography, using dichloromethane-methanol v / v 2:1 as eluent, collecting the eluent for high performance liquid chromatography detection, using C18 chromatographic column, 60% methanol / water, 254 nm wavelength as chromatographic conditions for detection, collecting the eluent containing the main peak, and drying to obtain a crude product; S7, purifying the crude product obtained in S6 by medium- and high-pressure preparative liquid phase purification.
6. The preparation method according to claim 5, characterized in that: The fermentation medium described in step S1 is composed of the following components in parts by weight: 90-100 g of rice, 100 ml of water, and sterilized by high-pressure steam at 120° C. for 20 min. The culture described in step S1 is placed at a constant temperature of 25° C. and cultured for 30 days.
7. The preparation method according to claim 5, characterized in that: In step S2, ethyl acetate is added to the fermentation product obtained in S1, the mass volume ratio of the fermentation product to ethyl acetate is 1:3, the extraction is ultrasonic extraction for 15 minutes, the number of extractions is 3 times, the power used for ultrasonic extraction is 400W, and the operating frequency is 40KHz.
8. The preparation method according to claim 5, characterized in that: In step S7, the high pressure preparative liquid chromatography purification is performed, and the mobile phase is a mixed solution of acetonitrile and water, wherein the volume percentage of acetonitrile is 70%.
9. Use of the unsaturated enal compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof in the preparation of an anti-inflammatory and expectorant drug; preferably, the drug is a drug for preventing and treating chronic obstructive pulmonary disease.
10. A drug, characterized in that The preparation is prepared by using the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient, and adding pharmaceutically acceptable excipients or auxiliary ingredients.
Citation Information
Patent Citations
Macrolide compound with anti-inflammatory activity as well as preparation method and application thereof
CN117721024A
Compound with anti-inflammatory activity as well as preparation method and application thereof
CN118221598A
